Pulmatrix Inc (PULM)

[riskon]

$PULM Cipla’s Kedar Upadhye:

Is there any increase in the company's expenditure on R&D as compared to the past?

We are increasing our R&D spend on two-three products, including generic Advair, whose clinical trial is very well on track. We have also been able to enrol the targeted number of patients. Apart from this, we have three-four additional products like inhaled itraconazole, which is being co-developed with our Pulmatrix in the US. So, there are three-four development programmes where we are focused and will continue to invest aggressively.

https://www.zeebiz.com/companies/news-cipla-is-investing-a-lot-on-rd-clinical-trial-of-generic-advair-s-is-going-on-track-kedar-upadhye-108171